Aptevo Therapeutics Inc. (APVO) vs Nexalin Technology, Inc. (NXL)
A side-by-side comparison of Aptevo Therapeutics Inc. and Nexalin Technology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APVO
Aptevo Therapeutics Inc.
$1.83HealthcareDelayed quote: Oct 6, 2026, 12:42 PM EDT
NXL
Nexalin Technology, Inc.
$4.98HealthcareDelayed quote: Oct 6, 2026, 12:38 PM EDT
Total return — APVO vs NXL
growth of $100 · dividends reinvested · last 4yAPVO -100.0% (-96.9%/yr)NXL -92.0% (-46.7%/yr)NXL compounded faster over this window
Log scale — wide-divergence pair
APVO NXL
APVO vs NXL: by the numbers
- •APVO is the larger company ($4M vs $4M market cap).
- •Both run net losses; APVO's is the smaller (0.00% vs -4139.38% net margin).
Metrics side by side
Valuation
| Metric | APVO | NXL |
|---|---|---|
| P/S ratio | N/A | 16.83 |
| P/B ratio | 0.66 | 2.40 |
Profitability
| Metric | APVO | NXL |
|---|---|---|
| Gross margin | 0.00% | 79.65% |
| Operating margin | 0.00% | -2781.69% |
| Net margin | 0.00% | -4139.38% |
| ROE | -437.15% | -591.60% |
| ROIC | -288.14% | -600.62% |
Growth (annualized)
| Metric | APVO | NXL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 10.22% |
| Total return CAGR (5Y) | -95.30% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.